Volver al Panel








10x Genomics, Inc. (TXG)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
TXG Intraday
No data available
SímboloTXG
Fecha de SalidaSep 12, 2019
CEODr. Serge Saxonov Ph.D.
Empleados a Tiempo Completo1.2k
SectorHealthcare
IndustriaMedical Devices
PaísUnited States
BolsaNasdaqGS
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | +2.42% | +1.69 US$ |
| 5 Días | +2.26% | +1.58 US$ |
| 1 Mes | -5.53% | -4.18 US$ |
| 6 Meses | +223.55% | +49.36 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de TXG...
Estadísticas Clave
Cap. de Mercado
9.32B
Relación P/E
N/A
Rend. de Div.
0.00%
Máx. 52 Semanas
$102.81
Mín. 52 Semanas
$12.34
Consenso de Analistas
CONSENSOCompra
ALCISTA633.3%
NEUTRAL1266.7%
BAJISTA00.0%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$50.00
$50.00
Objetivo Máx.
$110.00
$110.00
Actual$71.44
Objetivo Prom.$77.50
Recomendaciones de Analistas
Precio Objetivo:$77.50($50.00 - $110.00)
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre TXG
Únase a la comunidad para compartir su análisis
Últimas Noticias para TXG

1 unprofitable stock with exciting potential and 2 that underwhelm
StockStory•23 oct 2026, 18:40
Stephens Downgrades 10x Genomics to Equal Weight From Overweight, $65 Price Target
MT Newswires•23 oct 2026, 13:33

3 Healthcare Stocks That Concern Us
StockStory•19 oct 2026, 13:28
Cathie Wood-Led Ark Invest's Biggest Q3 Winners And Losers — PLTR, NVDA, TXG Led While TSLA, RKLB Dragged
Stocktwits•17 oct 2026, 08:29

10x Genomics (TXG) Stock Fair Value Rises After Analysts Back AI And Atera Demand
Simply Wall St.•16 oct 2026, 11:20

3 Reasons to Sell TXG and 1 Stock to Buy Instead
StockStory•15 oct 2026, 13:52

10x Genomics to Report Third Quarter 2026 Financial Results on November 5, 2026
PR Newswire•13 oct 2026, 20:05

Why Are 10x Genomics (TXG) Shares Soaring Today
StockStory•10 oct 2026, 00:27
BofA Securities Adjusts 10x Genomics Price Target to $80 From $50
MT Newswires•9 oct 2026, 12:09

Is 10x Genomics (TXG) Using Its Fred Hutch Oncology Alliance To Redefine Its Clinical Moat?
Simply Wall St.•9 oct 2026, 09:17